Cited by 366Metabolism and Genetic DisordersLysosomal Storage Disorders ResearchImmunodeficiency and Autoimmune Disorders

Reversal of Early Neurologic and Neuroradiologic Manifestations of X-Linked Adrenoleukodystrophy by Bone Marrow Transplantation

Open access
Aubourg, Patrick, Blanche, Stéphane, Jambaqué, Isabelle, Rocchiccioli, Francis, Kalifa, Gabriel, Naud-Saudreau, Catherine, Rolland, Marie-Odile, Debré, Mariane +4 more·1990·New England Journal of Medicine

Abstract

X-LINKED adrenoleukodystrophy is an inherited peroxisomal disease caused by a defective gene located within the Xq28 region of the X chromosome.1 Childhood adrenoleukodystrophy is characterized by ...

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejm199006283222607

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The only proven therapy available for X-ALD, at least for the CCALD phenotype, is bone marrow transplantation.

    “So far, the only proven therapy available for X-ALD, at least the CCALD phenotype, is bone marrow transplantation (45,46).”

    From Functional overlap between ABCD1 (ALD) and ABCD2 (ALDR) transporters: a therapeutic target for X-adrenoleukodystrophy (2004) · cites this paper as [45]

    The paper reports improvement after bone marrow transplantation in one child with early cerebral disease, while the Discussion (p. 6) says this single case supports further evaluation. It does not establish transplantation as a proven therapy or the only available therapy; the Bone Marrow Transplantation section (p. 3) explicitly calls its benefits unproved. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • In the short term, HSC transplantation reverses neuroinflammation and halts demyelination progression, as indicated by brain MRI.

    “In the short term, HSC transplantation reverses neuroinflammation and halts demyelination progression, as indicated by brain MRI [24,392,393].”

    From Revisiting the Pathogenesis of X-Linked Adrenoleukodystrophy (2025) · cites this paper as [24]

    The Neurodiagnostic Studies (pp. 3, 5) report that MRI lesions resolved over 6–18 months in one patient, and the Discussion (p. 6) concludes that early transplantation can reverse the demyelinating process. The paper does not establish reversal of neuroinflammation by MRI; it also reports that some lesions initially enlarged after transplantation. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Allogeneic transplantation of hematopoietic stem cells derived from bone marrow can induce remission of childhood cALD.

    “In 1990, a single patient showed that allogeneic transplantation of hematopoietic stem cells (HSCs) derived from bone marrow could induce remission of childhood cALD [24], opening the way for dozens of patients to receive the only treatment available for this disease [25] and”

    From Revisiting the Pathogenesis of X-Linked Adrenoleukodystrophy (2025) · cites this paper as [24]

  • The positive results of HSC transplantation into cALD patients indicated a role for brain microglia because microglia were thought to originate in bone marrow at that time.

    “The positive results of HSC transplantation into cALD patients [24,356] indicated a role for brain microglia because microglia were thought to originate in bone marrow at that time [357].”

    From Revisiting the Pathogenesis of X-Linked Adrenoleukodystrophy (2025) · cites this paper as [24]

  • Allogenic hematopoietic stem cell transplantation and autologous stem cell-based gene therapy can arrest the inflammatory demyelinating process in X-ALD with a typical delay of 12-18 months.

    “Allogenic hematopoietic stem cell transplantation [145,146] and autologous stem cell-based gene therapy [147] can arrest the inflammatory demyelinating process with a typical delay of 12–18 months, which has been attributed to the slow replacement of microglia with bone marrow-derived phagocytes [147,148].”

    From Peroxisomes in brain development and function (2016) · cites this paper as [146]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 29 references couldn’t be matched to a known paper.

Research works printed but not linked: 4

  1. [2]2. Moser HW, Naidu S, Kumar AJ, Rosenbaum AE. The adrenoleukodystrophies. Crit Rev Neurobiol 1987; 3:29-88.
  2. [7]7. Brown FR III, Van Duyn MA, Moser AB, et al. Adrenoleukodystrophy: efesi o a g g o is e o esta tion of carnitine and clofibrate on clinical status and plasma fatty acids. Johns Hopkins Med J 1982; 151:164-72.
  3. [8]8. Murphy JV, Marquardt KM, Moser HW, Van Duyn MA. Treatment of adrenoleukodystrophy by diet and plasmapheresis. Ann Neurol 1982; 12:220. abstract.
  4. [21]21. Wanders RJ, van Roermund ČW, van Wijland MJ, et al. Peroxisomal very nn n s a et a n a-n Zellweger syndrome and other peroxisomal disorders. Clin Chim Acta 1987; 166:255-63.

Cited by

Sorted by citations

Authors
Aubourg, P., Blanche, S., Jambaqué, I., Rocchiccioli, F., Kalifa, G., Naud-Saudreau, C., Rolland, M.-O., Debré, M., Chaussain, J.-L., Griscelli, C., Fischer, A., & Bougnères, P.-F.
Affiliations
  • Inserm (FR)
  • Hôpital Saint-Vincent-de-Paul (FR)
  • Centre Hospitalier de Bretagne Sud (FR)
Venue
New England Journal of Medicine
Published
1990-06-28
Volume
322
Issue
26
Pages
1860-1866
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2320665909
Cited by
366
References
29
Citations by year
2026: 9 · 2025: 8 · 2024: 13 · 2023: 4 · 2022: 13 · 2021: 6 · 2020: 7 · 2019: 7 · 2018: 13 · 2017: 9 · 2016: 10 · 2015: 10 · 2014: 12 · 2013: 10 · 2012: 8
FWCI
6.16
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
  • Health Sciences › Medicine › Physiology › Lysosomal Storage Disorders Research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
Keywords
X-linked adrenoleukodystrophy, bone marrow transplantation, peroxisomal disorders, neurologic manifestations, disease reversal
MeSH terms
Adrenoleukodystrophy, Diffuse Cerebral Sclerosis of Schilder, Child, Diseases in Twins, Fatty Acids, Humans, Leukocytes, Magnetic Resonance Imaging, Male, Neurologic Examination, Oxidation-Reduction, Psychometrics, Radiography, Bone Marrow Transplantation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review